K
Katsuyuki Kiura
Researcher at Okayama University
Publications - 593
Citations - 15272
Katsuyuki Kiura is an academic researcher from Okayama University. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 57, co-authored 564 publications receiving 13730 citations. Previous affiliations of Katsuyuki Kiura include Japanese Foundation for Cancer Research & Hiroshima University.
Papers
More filters
Journal ArticleDOI
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
Takashi Seto,Katsuyuki Kiura,Makoto Nishio,Kazuhiko Nakagawa,Makoto Maemondo,Akira Inoue,Toyoaki Hida,Nobuyuki Yamamoto,Hiroshige Yoshioka,Masao Harada,Yuichiro Ohe,Naoyuki Nogami,Kengo Takeuchi,Tadashi Shimada,Tomohiro Tanaka,Tomohide Tamura +15 more
TL;DR: CH5424802 is well tolerated and highly active in patients with advanced ALK-rearranged NSCLC, and the study is still ongoing, since 40 of the 46 patients in the phase 2 portion remain on treatment.
Journal Article
The Relationship between Epidermal Growth Factor Receptor Mutations and Clinicopathologic Features in Non–Small Cell Lung Cancers
Masaki Tokumo,Shinichi Toyooka,Katsuyuki Kiura,Hisayuki Shigematsu,Kunitoshi Tomii,Motoi Aoe,Kouichi Ichimura,Toshihide Tsuda,Masaaki Yano,Kazunori Tsukuda,Masahiro Tabata,Hiroshi Ueoka,Mitsune Tanimoto,Hiroshi Date,Adi F. Gazdar,Nobuyoshi Shimizu +15 more
TL;DR: In this article, the authors investigated the relationship between EGFR mutation and clinicopathologic features and found that EGFR mutations were significantly related to histology and smoke exposure and were a strong predictive factor for gefitinib responsiveness in NSCLC.
Journal ArticleDOI
Presence of Epidermal Growth Factor Receptor Gene T790M Mutation as a Minor Clone in Non–Small Cell Lung Cancer
Michio Inukai,Shinichi Toyooka,Sachio Ito,Hiroaki Asano,Shuji Ichihara,Junichi Soh,Hiroshi Suehisa,Mamoru Ouchida,Keisuke Aoe,Motoi Aoe,Katsuyuki Kiura,Nobuyoshi Shimizu,Hiroshi Date +12 more
TL;DR: The results indicate that the T790M mutation is sometimes present in a minor population of tumor cells during the development of NSCLC and suggest that the detection of small fractions of T790m mutant alleles may be useful for predicting gefitinib resistance of NSclCs with sensitive EGFR mutations.
Journal ArticleDOI
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw,Tae Min Kim,Lucio Crinò,Cesare Gridelli,Katsuyuki Kiura,Geoffrey Liu,Silvia Novello,Alessandra Bearz,Oliver Gautschi,Tony Mok,Makoto Nishio,Giorgio V. Scagliotti,David R. Spigel,S. Deudon,Cheng Zheng,Serafino Pantano,Patrick Urban,Cristian Massacesi,Kalyanee Viraswami-Appanna,Enriqueta Felip +19 more
TL;DR: Ceritinib showed a significant improvement in median progression-free survival compared with chemotherapy and was compared with single-agent chemotherapy in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed following crizotinib and platinum-based doublet chemotherapy.
Journal ArticleDOI
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Kadoaki Ohashi,Lecia V. Sequist,Maria E. Arcila,Teresa Moran,Juliann Chmielecki,Ya Lun Lin,Yumei Pan,Lu Wang,Elisa de Stanchina,Kazuhiko Shien,Keisuke Aoe,Shinichi Toyooka,Katsuyuki Kiura,Lynnette Fernandez-Cuesta,Panos Fidias,James Chih-Hsin Yang,Vincent A. Miller,Gregory J. Riely,Mark G. Kris,Jeffrey A. Engelman,Cindy L. Vnencak-Jones,Dora Dias-Santagata,Marc Ladanyi,William Pao +23 more
TL;DR: The data highlight the notion that, even though solid tumors share common signaling cascades, mediators of acquired resistance must be elucidated for each disease separately in the context of treatment.